Psoriasis: Targeting therapy towards the inflammatory cascade

American Journal of Clinical Dermatology

Volumn 11, Issue SUPPL. 1, 2010, Pages 11-13

  Miteva, Mariya ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

CHRONIC DISEASE; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; KERATINOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW;

EID: 77954266750     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/1153414-S0-000000000-00000     Document Type: Review

References (15)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. verview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
2. Tschachler E. Psoriasis: the epidermal component. Clin Dermatol 2007;25:589-95
3. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl. 2) : ii18-23; discussion ii4-5
4. De Rosa G, Mignogna C. The histopathology of psoriasis. Rheumatismo 2007; 59 (Suppl. 1) : 46-8
5. Nickoloff BJ, Xin H, Nestle FO, et al. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007;25:568-73
6. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-50
7. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9:461-7
8. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116:1218-22
9. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008;118:597-607
10. Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15
11. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44
12. Albanesi C, De Pita O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007;25:581-8
13. Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 2008;26:486-502
14. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-36
15. Gottlieb AB, Chamain F, Masus S, et al. TNF inhibition rapidly downregulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9